NEJM approval of trastuzumab deruxtecan in breast cancer

This new treatment slowed the progression of cancer in 75.8 percent of patients by age 12 months.

drugs trastuzumab deroxtecan Show “A Survive free progress And in general much higher than Chemotherapy The doctor chooses it “in infected patients metastatic breast cancer with Low HER2. This was detailed in the new study published in the scientific journal The New English Journal of Medicine. This research shows how, of the 557 randomized patients, 63 (11.3 percent) had hormone receptor-negative disease.

After analyzing the results, the researchers showed in patients Breast Cancer Low HER2 That “trastuzumab deruxtecan led to a Survive free progress. also submitted to medical writing Javier Cortesdirector of the International Breast Cancer Center (Ibcc) and principal architect of the study published in The New England Journal of Medicine, “Very positive results” have already been observed. In Curtis’s words, this drug stands for “A A new treatment scenario breast cancer. In fact, the standard has already been changed in the United States at this time and the drug is the drug of choice in patients previously treated with metastatic disease.”

The last study, which involved the participation of 557 patients, showed that in the hormonal receptor positive group, average survival Without progression it was 10.1 months in the trastuzumab deruxtecan arm and 5.4 months in the clinician’s select arm.” Survival in generalThe researchers estimated that they were “23.9 months and 17.5 months, respectively”.

In addition, experts showed that, of all patients, “the median progression-free survival was 9.9 months in the trastuzumab deroxtecan and 5.1 months in the physician’s selection arm, and survival was 23.4 months and 16.8 months, respectively. “

Have adverse effects appeared after taking the drug?

This new study on the effectiveness of the drug in Breast Cancer Low HER2 It also shows that ‘grade 3 or higher adverse events occurred in 52.6 percent of patients who received treatment. trastuzumab deroxtecan And in 67.4 percent of those who got Chemotherapy The doctor chooses it.

The researchers also stress that, “in 12.1 percent of patients treated with trastuzumab diroxecane, interstitial lung disease or drug-related pneumonia; 0.8 percent have fifth-grade events.”

The investigation was conducted in phase III trials in which patients participated metastatic breast cancer with Low expression of HER2 who received one or two previous lines from Chemotherapy. (Decreased HER2 expression was defined as a score of +1 on immunohistochemical analysis [IHC] or as an IHC score of 2+ and negative in situ hybridization results). “

were sick randomly assigned In a 2:1 ratio to receive trastuzumab deroxtecan wave Chosen chemotherapy by the doctor. The primary end point was progression-free survival in the hormone receptor-positive cohort. The main secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients.

Positive data in HER2 .-positive breast cancer

Similarly, the same scientific journal published another study stating that the same drug, trastuzumab deroxtecancame to stop cancer progression HER2-positive metastatic breast cancer in 75.8 percent of patients at 12 months of age compared to 34.1 percent who achieved this with current standard therapy. In this investigation, it was decided Compare drugs Previously used with trastuzumab emtancin in patients with HER2-positive metastatic breast cancer.

Although it may contain statements, statements, or notes from health institutions or professionals, the information in medical writing is edited and prepared by journalists. We recommend the reader to consult a health professional with any health-related questions.

Leave a Comment